Stay updated with breaking news from Chris linthwaite. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share: SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has joined the FLAMIN-GO Project consortium of academic and industry leaders in rheumatology, autoimmune disease research, and drug discovery and development to create an organ-on-a-chip solution toward personalized care and improved outcomes for rheumatoid arthritis (RA) patients. Organ-on-a-chip refers to a microfluidic culture device that simulates the microarchitecture and functions of living human organs, potentially offering an alternative to traditional animal testing. RA, an autoimmune inflammatory disorder characterized by synovial joint inflammation, affects ~0.5 to 1 percent of the global population. RA is a significant public health problem as it can lead to permanent disability. To gain insights into this disease, FLAMI ....
FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay March 01, 2021 08:30 ET | Source: Fluidigm Corporation Fluidigm Corporation Collaboration Agreement to Market Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase, Sample Collection, and Secure Delivery of Test Results SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the AZOVA™ COVID-19 Test Collection Kit for use with the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the company’s Biomark™ HD platform. ....
Industry News: George Mason University employs rapid-result COVID-19 tests to control the spread of virus on campus The testing capacity provided by the Fluidigm system aims to help the university limit the spread of the virus 11 Feb 2021 Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, has announced that George Mason University in Fairfax, Va., is providing saliva-based COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm As part of an expansion of testing capacity for GMU students and employees, the university purchased two Biomark HD systems and has equipped labs on the university’s Science and Technology Campus in Manassas, Va., to process the Advanta Dx Assay, with initial plans to run approximately 10,000 tests per week. ....
Fluidigmâs saliva based RT-PCR kit receives approval in India 24 December 2020 | News Source credit: Fluidigm With the increased reliance on saliva based testing, US based Fluidigm has revealed that its Advanta Dx SARS-COV-2 RT-PCR kit, which is a saliva based diagnostic test has been authorized for use in India. This kit facilitates SARS-CoV-2 detection from saliva samples easing the sample collection process & eliminating the need for Viral RNA extraction process. The kit is compatible with Fluidigm’s high-throughput Biomark HD platform. Fluidigm claims that with certain configurations, the Biomark HD system can run a maximum of 6000 samples and controls per day. ....
Fluidigm s FDA-EUA Authorized Saliva-based SARS-CoV-2 RT-PCR Assay - Now for use in India ANI | Updated: Dec 24, 2020 17:27 IST New Delhi [India], December 24 (ANI/NewsVoir): It s been a year now since the first few human cases of COVID-19 infection were reported amidst the busy wholesale food market of China s Wuhan city. The disease caused by SARS-CoV-2 virus, thought to have its origin in Bats, soon spread to cause worldwide outbreaks & escalated to a global pandemic. The latest statistics indicate 46.5 Million cases reported to date worldwide with the global mortality rate around 2.5% and India ranking second at 8.23M cases till date. COVID-19 has brought with it the need for SARS-CoV-2 tracking, surveillance & diagnosis. Countries that adopted testing strategies early on were able to test, track & isolate individuals that showed disease symptoms & hence were better able to contain the disease spread. While antibody testing ....